SPDR S&P Biotech ETF
Price through Oct 27, 2026 · Flows through Oct 26, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Oct 27, 2026. Holdings snapshot retrieved Oct 27, 2026.
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
XBI price
Table
| Date | XBI close |
|---|---|
| Sep 28, 2026 | $156.61 |
| Sep 29, 2026 | $156.81 |
| Sep 30, 2026 | $157.68 |
| Oct 1, 2026 | $154.51 |
| Oct 2, 2026 | $154.43 |
| Oct 5, 2026 | $156.19 |
| Oct 6, 2026 | $150.90 |
| Oct 7, 2026 | $150.23 |
| Oct 8, 2026 | $149.29 |
| Oct 9, 2026 | $153.77 |
| Oct 12, 2026 | $151.40 |
| Oct 13, 2026 | $146.80 |
| Oct 14, 2026 | $146.77 |
| Oct 15, 2026 | $149.78 |
| Oct 16, 2026 | $144.32 |
| Oct 19, 2026 | $147.86 |
| Oct 20, 2026 | $153.24 |
| Oct 21, 2026 | $152.78 |
| Oct 22, 2026 | $151.64 |
| Oct 23, 2026 | $149.54 |
| Oct 26, 2026 | $150.47 |
| Oct 27, 2026 | $154.84 |
Daily net flows, 1M
Net inflow over the range: +$312M
- Inflow / above zero
- Outflow / below zero
Show as table
| Label | Value ($) |
|---|---|
| Sep 28 | $58.5M |
| Sep 29 | $117M |
| Sep 30 | −$197.5M |
| Oct 1 | −$66.3M |
| Oct 2 | $19.4M |
| Oct 5 | $104.6M |
| Oct 6 | $111.7M |
| Oct 7 | $75M |
| Oct 8 | −$170.2M |
| Oct 9 | $136.8M |
| Oct 12 | $126.2M |
| Oct 13 | $96.8M |
| Oct 14 | $18.4M |
| Oct 15 | $67M |
| Oct 16 | −$66.2M |
| Oct 19 | −$264.6M |
| Oct 20 | $177.4M |
| Oct 21 | $273.4M |
| Oct 22 | −$38M |
| Oct 23 | −$45M |
| Oct 26 | −$222.7M |
Money keeps arriving — +$312M of net inflows over the past month, about 3.1% of the fund's asset base, while the price has returned +27.0% so far this year. At 0.35% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | MRNAMODERNA | 1.41% | $207.97 | +4.6% | ||
| 2 | TWSTTWIST BIOSCIENCE | 1.40% | $159.85 | +10.1% | ||
| 3 | GRALGRAIL INC | 0.90% | $150.61 | +7.6% | ||
| 4 | IOVAIOVANCE BIOTHERAPEUTICS | 0.56% | $14.58 | +5.8% | ||
| 5 | NTRANATERA | 1.16% | $410.82 | +1.5% | ||
| 6 | HALOHALOZYME THERAPEUTICS | 1.03% | $128.50 | +0.4% | ||
| 7 | KYMRKYMERA THERAPEUTICS | 1.35% | $117.57 | +2.4% | ||
| 8 | ORKAOruka Therapeutics | 1.37% | $95.81 | +6.1% | ||
| 9 | KODKODIAK SCIENCES | 0.54% | $91.32 | +1.9% | ||
| 10 | REGNREGENERON PHARMACEUTICALS | 0.96% | $816.10 | +1.0% | ||
| 11 | PCVXVAXCYTE | 1.18% | $60.67 | +1.2% | ||
| 12 | PTGXPROTAGONIST THERAPEUTICS | 1.07% | $141.12 | +0.6% | ||
| 13 | AMGNAMGEN | 0.99% | $447.95 | +0.7% | ||
| 14 | SYRESPYRE THERAPEUTICS INC | 1.09% | $99.05 | +6.6% | ||
| 15 | GILDGILEAD SCIENCES | 0.96% | $159.08 | +0.2% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.
Sign in to see all 135Sector weights
- Healthcare100%
- Health Technology99.1%
- Health Services0.86%
- Other0.07%
Show as table
| Item | Value (%) |
|---|---|
| Healthcare | 100% |
| Health Technology | 99.1% |
| Health Services | 0.86% |
| Other | 0.07% |
Country weights
- United States97.18%
- United Kingdom1.29%
- Switzerland1.25%
- Bermuda0.34%
- Ireland0.27%
- Netherlands0.23%
Show as table
| Item | Value (%) |
|---|---|
| United States | 97.18% |
| United Kingdom | 1.29% |
| Switzerland | 1.25% |
| Bermuda | 0.34% |
| Ireland | 0.27% |
| Netherlands | 0.23% |
| 1 week | +1.3% |
| 1 month | -0.1% |
| 3 months | +2.8% |
| 6 months | +16.2% |
| YTD | +27.0% |
| 1 year | +38.8% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | −$32M |
| 1 month | +$312M |
| 3 months | +$239M |
| YTD | +$619M |
| 1 year | +$1.1B |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
Monthly net flows
- Inflow / above zero
- Outflow / below zero
Show as table
| Label | Value ($) |
|---|---|
| Nov | $785.9M |
| Dec | −$387.2M |
| Jan | $288.5M |
| Feb | −$443.7M |
| Mar | −$592.4M |
| Apr | $628.5M |
| May | −$228.6M |
| Jun | $922.5M |
| Jul | −$365.8M |
| Aug | $766.6M |
| Sep | −$690.4M |
| Oct | $333.8M |
The top holding is 1.5% of the book; the top ten carry 13%. Spread across 151+ names, it behaves like roughly 110 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $52M | $53M |
| AMGN AMGEN | $64M | $2M |
| INSM INSMED | $8M | $5M |
| SLS SELLAS LIFE SCIENCES GROUP | $2M | $4M |
| ABBV ABBVIE | $3M | $3M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat XBI on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW SPDR Portfolio Developed World ex-US ETF | 0.03% | $40.7B | +$609M | -32bp on fee · 4× the assets · +$609M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -32bp on fee · 2× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.4B | +$497M | -31bp on fee · 3× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$47M | -31bp on fee · 2× the assets · +$47M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -31bp on fee · 2× the assets · +$412M in over the month | Head-to-head |